Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4106241
Max Phase: Preclinical
Molecular Formula: C46H79N3O15S
Molecular Weight: 946.21
Molecule Type: Small molecule
Associated Items:
ID: ALA4106241
Max Phase: Preclinical
Molecular Formula: C46H79N3O15S
Molecular Weight: 946.21
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC(C)(O)C(CC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@]12C)SC[C@H](NC(=O)CC[C@H](N)C(=O)O)C(=O)NCC(=O)O
Standard InChI: InChI=1S/C46H79N3O15S/c1-41(2)28-12-17-44(6)29(43(28,5)15-13-30(41)64-40-37(57)36(56)35(55)27(21-50)63-40)19-26(51)34-23(11-16-45(34,44)7)46(8,62)18-14-31(42(3,4)61)65-22-25(38(58)48-20-33(53)54)49-32(52)10-9-24(47)39(59)60/h23-31,34-37,40,50-51,55-57,61-62H,9-22,47H2,1-8H3,(H,48,58)(H,49,52)(H,53,54)(H,59,60)/t23-,24-,25-,26+,27+,28-,29+,30-,31?,34-,35+,36-,37+,40-,43-,44+,45+,46-/m0/s1
Standard InChI Key: IMBKMQHOHNTZRB-SHXYBYRDSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 946.21 | Molecular Weight (Monoisotopic): 945.5232 | AlogP: 1.11 | #Rotatable Bonds: 19 |
Polar Surface Area: 318.89 | Molecular Species: ZWITTERION | HBA: 15 | HBD: 12 |
#RO5 Violations: 3 | HBA (Lipinski): 18 | HBD (Lipinski): 13 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 1.80 | CX Basic pKa: 9.31 | CX LogP: -2.68 | CX LogD: -5.92 |
Aromatic Rings: 0 | Heavy Atoms: 65 | QED Weighted: 0.08 | Np Likeness Score: 2.04 |
1. Li L, Chen X, Zhou J, Zhong D.. (2012) In vitro studies on the oxidative metabolism of 20(s)-ginsenoside Rh2 in human, monkey, dog, rat, and mouse liver microsomes, and human liver s9., 40 (10): [PMID:22829543] [10.1124/dmd.112.046995] |
Source(1):